Supported by a healthy balance sheet, Marc Booth says the firm plans on a higher volume of smaller deals with three new areas identified for future growth
Securing a FRAND licence with the world’s fifth largest handset maker could be a shot in the arm for the Swedish company, which has struggled to get royalties out of Chinese firms like Xiaomi and TCL
An AI health-tech startup recently named one of the world's most promising had its roots in the re-organisation of Xerox's research centre in India
The NPE, which bought Unwired Planet in 2016 and owns thousands of patents previously held by Ericsson and Panasonic, sold to Brevet Capital for an undisclosed sum
Aggressive move by the country’s largest public IP services group seems designed to thwart the merger of two smaller rivals. But further consolidation in the space still looks likely
In a Delaware case Boehringer Ingelheim accuses the Illinois company of improper conduct in deliberately constructing a patent thicket to protect against generic versions of its blockbuster drug.
With new guidelines set to reshape patent examination, the USPTO head makes the case for revisiting subject matter precedent
The company behind Tik Tok bought out much of a struggling smartphone maker’s patent portfolio in January. USPTO assignments from last week show what assets Beijing-based ByteDance came away with
The telecoms giant is building its presence in the secondary market with a host of companies now seeking out its high-quality patents
An annual survey conducted by CNIPA pegs the licensing rate of Chinese patents at 5.5%. That's not far off estimates of US patent utilisation
Former IV unit teams up with alternative asset business to give large and small innovators way of attracting finance on Blockchain-based initiative
The settlement deal ends litigation by the Singapore company’s ZiiLabs unit against Nvidia, and will net shareholders around $17.5 million
The iPhone maker moves for declaratory judgment claiming non infringement of grants relating to charging technology
The high-end maker of tablets and styluses for artists and designers makes its latest patent acquisition amidst new US litigation and a push to reach more consumers with competitively priced offerings
Coherus launched Delaware action against Amgen in what is likely to become an increasingly familiar life sciences litigation scenario.